Loading
Every dated change on the records linked to Hepatoblastoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Upfront resection for PRETEXT I-II (COG) or cisplatin monotherapy ×4-6 with delayed resection (SIOPEL-3); sodium thiosulfate after each cisplatin dose for otoprotection.
Complete remission at the end of therapy in 79 percent of 62 high-risk patients; complete resection 74 percent; three-year event-free survival 76 percent and overall survival 83 percent.
A milestone in how this cancer is treated.
Complete resection 95 percent with cisplatin alone against 93 percent with cisplatin plus doxorubicin; three-year overall survival 95 against 93 percent; grade 3 or 4 toxicity 20.
A milestone in how this cancer is treated.